SCHEMBL1582297

SCHEMBL1582297

CC(C)S(=O)(=O)c1ccc(C2(C(=O)O)CC2C2CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.47
MMP1 P03956 2/20 0.34
MMP2 P08253 2/20 0.34
MMP3 P08254 2/20 0.34
ABL1 P00519 1/20 0.34
CNR2 P34972 1/20 0.34
HSD11B1 P28845 2/20 0.33
TSHR P16473 2/20 0.32
POLB P06746 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
EPHX2 P34913 1/20 0.32
SLC6A2 P23975 1/20 0.32
CXCR1 P25024 1/20 0.31
CXCR2 P25025 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12720772 0.89 GCK (0.46) GCKMMP1MMP2MMP3ABL1
SCHEMBL1581747 0.86 GCK (0.60) GCKCNR2HSD11B1KMT2AALDH1A1
SCHEMBL2654841 0.86 GCK (0.60) GCKCNR2HSD11B1KMT2AALDH1A1
SCHEMBL1582235 0.84 GCK (0.58) GCKCNR2HSD11B1KMT2AALDH1A1
SCHEMBL1581983 0.82 GCK (0.49) GCKTSHRPOLBKMT2AALDH1A1
SCHEMBL1344865 0.82 GCK (0.46) GCKCNR2HSD11B1KMT2AALDH1A1
SCHEMBL1582299 0.81 GCK (0.45) GCKPOLBKMT2AALDH1A1SLC6A2
SCHEMBL1107322 0.78 GCK (0.57) GCKCNR2HSD11B1POLBKMT2A
SCHEMBL1582098 0.78 GCK (0.36) GCKMMP1MMP2MMP3ABL1
SCHEMBL1581632 0.78 GCK (0.81) GCKTSHRPOLBHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US claimed
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 GCK 1/4885MMP1 1939/4885MMP2 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.